FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886196619> ?p ?o ?g. }

• W2886196619 abstract "The PD-1/PD-L1 molecular pathway is one of the primary mechanisms of immune evasion deployed by cancer cells. Induction of PD-L1 expression on cancer cells is associated with inhibition of immune responses against cancer, thus permitting cancer progression and metastasis. Activation of PD-1/PD-L1 pathway induces apoptosis of activated T-cells, inhibits their proliferation, facilitates T-cell anergy and exhaustion and enhances the function of regulator T-cells. Therefore, blocking this pathway restores the proliferation and cytotoxicity of CTLs, inhibits the function of Tregs and results in decreased T-cell apoptosis. A number of cancer immunotherapy agents targeting PD-1/PD-L1 have been developed and approved for a number of malignancies (PD-1: Nivolumab, Pembrolizumab, PD-L1: Atezolizumab, Avelumab, Durvalumab). However, there is a still a need for potent, selective small molecule inhibitors of the PD-1/PD-L1 pathway. The approved therapies require bolus intravenous injections, are administered in high dose and have a long half life. The long residence time of these mAbs could contribute to the well-documented drug-related adverse effects. Small molecule inhibitors, therefore, can provide increased oral bioavailability, increased bio-efficiency and shorted half life activity for a more controllable treatment, particular in the case of auto-immune or other adverse effects. Rational and structure guided de novo design approaches were used to design novel small molecule PD-1/PD-L1 pathway inhibitors; potency of these inhibitors was assessed in an in-vitro TR-FRET assay. Checkpoints signaling reporter assays as well as ex-vivo co-culture assays were used to assess the ability of the compounds to restore T-cell proliferation and function. Three novel chemical series as potent PD-1/PD-L1 pathway inhibitors are being developed for the treatment of cancer. Compounds from these series showed strong in vitro potency of 0.01 to 0.2 µM against PD-1/PD-L1. JBI-426 exhibited an IC50 of 0.04 µM and no cytotoxicity against cancer cell proliferation per se. JBI-426 showed good in vitro ADME properties in terms of aqueous solubility, metabolic stability, permeability and excellent oral bioavailability in mouse pharmacokinetics. In a RENCA syngeneic model, oral administration of JBI-426 at 50 mg/kg resulted in a strong tumor growth inhibition, comparable (or better) than the PD-L1 mAb, and was well tolerated. The effect of JBI-426 on tumor infiltrating lymphocytes was also assessed; a significant increase in CD8+ cytotoxic lymphocytes was observed. Further studies to assess additional compounds from the three chemical series are underway. The oral administration route of these PD-1/PD-L1 inhibitors would provide an attractive alternate to the currently available antibodies in treating cancer either as a stand-alone therapy or in combination with other immuno-modulatory agents, as well as other standard of care agents. Citation Format: Sivanandhan Dhanalakshmi, Shivani Garapaty, Chandregowda Venkateshappa, Guru Pavan Seerapu, Reshma Das, Pradeep Nagaraj, Ronodip Kar, Anuj Kumar Singh, Venkatesha Ashokkumar Venkatesubbiah, Ramakishore VP Putta, Muralidhar Pendyala, Girisha Lokesh, Hari Madaka, Harikrishna Reddy Thummuru, Shikas AP, Prateeksha Anchan, Prathima Bhat, Rudresha G, Mohd Zainuddin, Krishnakumar V, Ramachandraiah Gosu, Rajendra Kristam, Jeyaraj DA, Sriram Rajagopal. Novel, heterocyclic small molecule inhibitors of PD-1 and PD-L1 pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5552." @default.
• W2886196619 created "2018-08-22" @default.
• W2886196619 creator A5001884936 @default.
• W2886196619 creator A5003031576 @default.
• W2886196619 creator A5007596056 @default.
• W2886196619 creator A5013644550 @default.
• W2886196619 creator A5014877314 @default.
• W2886196619 creator A5025844559 @default.
• W2886196619 creator A5029959407 @default.
• W2886196619 creator A5038613035 @default.
• W2886196619 creator A5043552005 @default.
• W2886196619 creator A5047654747 @default.
• W2886196619 creator A5054007447 @default.
• W2886196619 creator A5062047156 @default.
• W2886196619 creator A5066139631 @default.
• W2886196619 creator A5066581985 @default.
• W2886196619 creator A5068021269 @default.
• W2886196619 creator A5070938627 @default.
• W2886196619 creator A5071182434 @default.
• W2886196619 creator A5073147070 @default.
• W2886196619 creator A5074272926 @default.
• W2886196619 creator A5078061243 @default.
• W2886196619 creator A5081904152 @default.
• W2886196619 creator A5082021811 @default.
• W2886196619 creator A5086358742 @default.
• W2886196619 creator A5088904795 @default.
• W2886196619 date "2018-07-01" @default.
• W2886196619 modified "2023-09-27" @default.
• W2886196619 title "Abstract 5552: Novel, heterocyclic small molecule inhibitors of PD-1 and PD-L1 pathway" @default.
• W2886196619 doi "https://doi.org/10.1158/1538-7445.am2018-5552" @default.
• W2886196619 hasPublicationYear "2018" @default.
• W2886196619 type Work @default.
• W2886196619 sameAs 2886196619 @default.
• W2886196619 citedByCount "0" @default.
• W2886196619 crossrefType "proceedings-article" @default.
• W2886196619 hasAuthorship W2886196619A5001884936 @default.
• W2886196619 hasAuthorship W2886196619A5003031576 @default.
• W2886196619 hasAuthorship W2886196619A5007596056 @default.
• W2886196619 hasAuthorship W2886196619A5013644550 @default.
• W2886196619 hasAuthorship W2886196619A5014877314 @default.
• W2886196619 hasAuthorship W2886196619A5025844559 @default.
• W2886196619 hasAuthorship W2886196619A5029959407 @default.
• W2886196619 hasAuthorship W2886196619A5038613035 @default.
• W2886196619 hasAuthorship W2886196619A5043552005 @default.
• W2886196619 hasAuthorship W2886196619A5047654747 @default.
• W2886196619 hasAuthorship W2886196619A5054007447 @default.
• W2886196619 hasAuthorship W2886196619A5062047156 @default.
• W2886196619 hasAuthorship W2886196619A5066139631 @default.
• W2886196619 hasAuthorship W2886196619A5066581985 @default.
• W2886196619 hasAuthorship W2886196619A5068021269 @default.
• W2886196619 hasAuthorship W2886196619A5070938627 @default.
• W2886196619 hasAuthorship W2886196619A5071182434 @default.
• W2886196619 hasAuthorship W2886196619A5073147070 @default.
• W2886196619 hasAuthorship W2886196619A5074272926 @default.
• W2886196619 hasAuthorship W2886196619A5078061243 @default.
• W2886196619 hasAuthorship W2886196619A5081904152 @default.
• W2886196619 hasAuthorship W2886196619A5082021811 @default.
• W2886196619 hasAuthorship W2886196619A5086358742 @default.
• W2886196619 hasAuthorship W2886196619A5088904795 @default.
• W2886196619 hasConcept C121608353 @default.
• W2886196619 hasConcept C126322002 @default.
• W2886196619 hasConcept C185592680 @default.
• W2886196619 hasConcept C203014093 @default.
• W2886196619 hasConcept C2775949291 @default.
• W2886196619 hasConcept C2776090121 @default.
• W2886196619 hasConcept C2777701055 @default.
• W2886196619 hasConcept C2777742743 @default.
• W2886196619 hasConcept C2780030458 @default.
• W2886196619 hasConcept C2780057760 @default.
• W2886196619 hasConcept C2780674031 @default.
• W2886196619 hasConcept C502942594 @default.
• W2886196619 hasConcept C71924100 @default.
• W2886196619 hasConcept C8891405 @default.
• W2886196619 hasConcept C96232424 @default.
• W2886196619 hasConcept C98274493 @default.
• W2886196619 hasConceptScore W2886196619C121608353 @default.
• W2886196619 hasConceptScore W2886196619C126322002 @default.
• W2886196619 hasConceptScore W2886196619C185592680 @default.
• W2886196619 hasConceptScore W2886196619C203014093 @default.
• W2886196619 hasConceptScore W2886196619C2775949291 @default.
• W2886196619 hasConceptScore W2886196619C2776090121 @default.
• W2886196619 hasConceptScore W2886196619C2777701055 @default.
• W2886196619 hasConceptScore W2886196619C2777742743 @default.
• W2886196619 hasConceptScore W2886196619C2780030458 @default.
• W2886196619 hasConceptScore W2886196619C2780057760 @default.
• W2886196619 hasConceptScore W2886196619C2780674031 @default.
• W2886196619 hasConceptScore W2886196619C502942594 @default.
• W2886196619 hasConceptScore W2886196619C71924100 @default.
• W2886196619 hasConceptScore W2886196619C8891405 @default.
• W2886196619 hasConceptScore W2886196619C96232424 @default.
• W2886196619 hasConceptScore W2886196619C98274493 @default.
• W2886196619 hasLocation W28861966191 @default.
• W2886196619 hasOpenAccess W2886196619 @default.
• W2886196619 hasPrimaryLocation W28861966191 @default.
• W2886196619 hasRelatedWork W2584071843 @default.
• W2886196619 hasRelatedWork W2785897891 @default.
• W2886196619 hasRelatedWork W2843129625 @default.
• W2886196619 hasRelatedWork W2979186475 @default.
• W2886196619 hasRelatedWork W2993790564 @default.
• W2886196619 hasRelatedWork W3104083510 @default.

• next